Earswitch, a medtech startup developing in-ear vital sign monitoring technology, has secured funding led by PXN Ventures, with participation from South East Angels, Surrey 100 Angels, and Britbots. The investment will support product development, clinical validation, and commercial readiness, including the advancement of digital blood pressure monitoring from within the ear.
Using its proprietary EarMetrics® in-ear sensing technology, Earswitch is developing a non-invasive approach to measuring blood pressure continuously through the ear canal. The technology is designed to provide real-time monitoring without interrupting daily activities, with applications in chronic condition management, remote patient monitoring, and preventative healthcare.
The investment also supports Earswitch’s participation in the Innovate UK-funded Investor Partnerships - Health Technologies programme within the West Yorkshire ecosystem. Through the programme, Earswitch is developing an approach to measuring blood pressure continuously using the ear canal, which the business says is increasingly recognised for its stability and proximity to key physiological signals.
Bringing together investors with experience across healthcare, robotics, and early-stage innovation, the syndicate includes PXN Ventures as lead investor alongside South East Angels, Surrey 100 Angels, and Britbots.
We’re delighted to have the backing of such an experienced and aligned group of investors. This funding not only strengthens our ability to bring our technology closer to market, but also validates the enormous potential of in-ear sensing as a new frontier in vital sign monitoring.
